Cost-Effectiveness of Statin Therapy for ASCVD

In response to a microsimulation study finding statin therapy cost-effective for over 60% of US adults aged 40-75, the authors highlight that real-world drug costs may substantially exceed the wholesale acquisition costs used in the modl and that widespread lack of transparency in drug pricing, including legislatively restricted disclosure of average manufacturer prices and Medicaid rebates, complicates interpretation of cost-effectiveness analyses that rely on prescription medication costs.